{"transactions":[{"id":4628933,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33751,"kind":"person","name":"Loggia Nicoletta","position":1,"cik":"0001979825","reported_name":"Loggia Nicoletta","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T21:57:46.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":380,"price":8.676,"value":3296.88,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":380,"derivative":{"exercise_price":10.44,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":380},"source":{"system":"sec-edgar","filing":"0001193125-26-412658","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1979825/000119312526412658/ownership.xml","form_type":"4"}},{"id":4628941,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33888,"kind":"person","name":"PAPA JOSEPH C","position":1,"cik":"0001242215","reported_name":"PAPA JOSEPH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T21:56:31.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":1325,"price":8.676,"value":11495.7,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":1325,"derivative":{"exercise_price":10.44,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":1325},"source":{"system":"sec-edgar","filing":"0001193125-26-412655","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526412655/ownership.xml","form_type":"4"}},{"id":4628950,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T21:54:38.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":2189,"price":8.676,"value":18991.764,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":2189,"derivative":{"exercise_price":10.44,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":2189},"source":{"system":"sec-edgar","filing":"0001193125-26-412654","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526412654/ownership.xml","form_type":"4"}},{"id":4616292,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-11T22:12:13.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option vested and became exercisable on October 10, 2020, with another 25% vesting on September 14, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":1638968,"derivative":{"exercise_price":1.55,"expiration_date":"2030-10-10","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001873905-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873905/000187390526000002/ownership.xml","form_type":"4"}},{"id":4616291,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:12:13.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":59379,"price":10.4564,"value":620890.5756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 herein."}],"balance_after":113321,"source":{"system":"sec-edgar","filing":"0001873905-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873905/000187390526000002/ownership.xml","form_type":"4"}},{"id":4616290,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:12:13.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":220866,"price":11.4997,"value":2539892.7402,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.20 to $12.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."}],"balance_after":172700,"source":{"system":"sec-edgar","filing":"0001873905-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873905/000187390526000002/ownership.xml","form_type":"4"}},{"id":4616289,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:12:13.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":125000,"price":1.55,"value":193750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026."}],"balance_after":393566,"source":{"system":"sec-edgar","filing":"0001873905-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873905/000187390526000002/ownership.xml","form_type":"4"}},{"id":4614654,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":40268,"kind":"person","name":"Zimmermann Martine","position":1,"cik":"0001994049","reported_name":"Zimmermann Martine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-10T20:24:20.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":64000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":64000,"derivative":{"exercise_price":12.6,"expiration_date":"2036-09-08","underlying":"Common Stock","underlying_shares":64000},"source":{"system":"sec-edgar","filing":"0001193125-26-387924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1994049/000119312526387924/ownership.xml","form_type":"4"}},{"id":681658,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:30:03.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":12,"value":84000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026."}],"balance_after":76865,"source":{"system":"sec-edgar","filing":"0001923794-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000192379426000004/ownership.xml","form_type":"4"}},{"id":712327,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":31377,"kind":"person","name":"Sims Mark E.","position":1,"cik":"0002139479","reported_name":"Sims Mark E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-08T20:12:32.000Z","date":"2026-07-06","kind":"grant","planned":false,"acquired":true,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option shall vest and become exercisable on July 6, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":285000,"derivative":{"exercise_price":10.03,"expiration_date":"2036-07-06","underlying":"Common Stock","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0002139479-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000213947926000004/ownership.xml","form_type":"4"}},{"id":722182,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":34272,"kind":"person","name":"Barone Francesca","position":1,"cik":"0001909680","reported_name":"Barone Francesca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:22:57.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":23447,"price":10.0554,"value":235768.9638,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."}],"balance_after":77362,"source":{"system":"sec-edgar","filing":"0001909680-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909680/000190968026000002/ownership.xml","form_type":"4"}},{"id":721473,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:22:18.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":10.0216,"value":70151.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.07 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."}],"balance_after":83865,"source":{"system":"sec-edgar","filing":"0001923794-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000192379426000002/ownership.xml","form_type":"4"}},{"id":721152,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:21:13.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":2199,"price":8.639,"value":18997.161,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":2199,"derivative":{"exercise_price":10.3,"exercise_date":"2026-07-01","expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":2199},"source":{"system":"sec-edgar","filing":"0001494695-26-000018","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000018/ownership.xml","form_type":"4"}},{"id":720923,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33888,"kind":"person","name":"PAPA JOSEPH C","position":1,"cik":"0001242215","reported_name":"PAPA JOSEPH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:20:42.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":1331,"price":8.639,"value":11498.509,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":1331,"derivative":{"exercise_price":10.3,"exercise_date":"2026-07-01","expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":1331},"source":{"system":"sec-edgar","filing":"0001242215-26-000018","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242215/000124221526000018/ownership.xml","form_type":"4"}},{"id":720566,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33751,"kind":"person","name":"Loggia Nicoletta","position":1,"cik":"0001979825","reported_name":"Loggia Nicoletta","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:20:02.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":381,"price":8.639,"value":3291.459,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":381,"derivative":{"exercise_price":10.3,"exercise_date":"2026-07-01","expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":381},"source":{"system":"sec-edgar","filing":"0001979825-26-000006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000197982526000006/ownership.xml","form_type":"4"}},{"id":727899,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35728,"kind":"person","name":"Radhakrishnan Maha","position":1,"cik":"0002013423","reported_name":"Radhakrishnan Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:36:05.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0002013423-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013423/000201342326000004/ownership.xml","form_type":"4"}},{"id":727234,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33751,"kind":"person","name":"Loggia Nicoletta","position":1,"cik":"0001979825","reported_name":"Loggia Nicoletta","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:34:59.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001979825-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000197982526000004/ownership.xml","form_type":"4"}},{"id":727494,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33888,"kind":"person","name":"PAPA JOSEPH C","position":1,"cik":"0001242215","reported_name":"PAPA JOSEPH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:33:47.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001242215-26-000016","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242215/000124221526000016/ownership.xml","form_type":"4"}},{"id":727651,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35655,"kind":"person","name":"Benz Edward J. JR","position":1,"cik":"0001691160","reported_name":"Benz Edward J. JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:32:10.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001691160-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691160/000169116026000002/ownership.xml","form_type":"4"}},{"id":727851,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35711,"kind":"person","name":"Martell Christopher","position":1,"cik":"0001873465","reported_name":"Martell Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:31:10.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001873465-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873465/000187346526000002/ownership.xml","form_type":"4"}},{"id":727711,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":22260,"kind":"person","name":"Gaeta Renee","position":1,"cik":"0001742428","reported_name":"Gaeta Renee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:30:02.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001742428-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742428/000174242826000004/ownership.xml","form_type":"4"}},{"id":727231,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35576,"kind":"person","name":"Nabel Gary J.","position":1,"cik":"0001867450","reported_name":"Nabel Gary J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:28:29.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001867450-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000186745026000002/ownership.xml","form_type":"4"}},{"id":727752,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35681,"kind":"person","name":"Nguyen Diem","position":1,"cik":"0001814338","reported_name":"Nguyen Diem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:27:29.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001814338-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814338/000181433826000004/ownership.xml","form_type":"4"}},{"id":727605,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T20:26:36.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":32000,"derivative":{"exercise_price":9.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001494695-26-000015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000015/ownership.xml","form_type":"4"}},{"id":819482,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T21:17:15.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":4618,"price":4.114,"value":18998.452,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":4618,"derivative":{"exercise_price":4.9,"exercise_date":"2026-04-01","expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":4618},"source":{"system":"sec-edgar","filing":"0001494695-26-000007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000149469526000007/ownership.xml","form_type":"4"}},{"id":819224,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33888,"kind":"person","name":"PAPA JOSEPH C","position":1,"cik":"0001242215","reported_name":"PAPA JOSEPH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T21:10:45.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":2795,"price":4.114,"value":11498.63,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":2795,"derivative":{"exercise_price":4.9,"exercise_date":"2026-04-01","expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":2795},"source":{"system":"sec-edgar","filing":"0001242215-26-000010","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242215/000124221526000010/ownership.xml","form_type":"4"}},{"id":818629,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33751,"kind":"person","name":"Loggia Nicoletta","position":1,"cik":"0001979825","reported_name":"Loggia Nicoletta","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T21:08:06.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":779,"price":4.114,"value":3204.806,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."}],"balance_after":779,"derivative":{"exercise_price":4.9,"exercise_date":"2026-04-01","expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":779},"source":{"system":"sec-edgar","filing":"0001979825-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000197982526000002/ownership.xml","form_type":"4"}},{"id":879577,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-27T00:38:59.000Z","date":"2026-02-23","kind":"purchase","planned":false,"acquired":true,"shares":550458,"price":5.45,"value":2999996.1,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":2763527,"source":{"system":"sec-edgar","filing":"0001193125-26-078246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000119312526078246/ownership.xml","form_type":"4"}},{"id":929115,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-28T22:04:50.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":154000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":154000,"derivative":{"exercise_price":6.01,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":154000},"source":{"system":"sec-edgar","filing":"0001193125-26-027412","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000119312526027412/ownership.xml","form_type":"4"}},{"id":928639,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-28T22:01:24.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":629000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":629000,"derivative":{"exercise_price":6.01,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":629000},"source":{"system":"sec-edgar","filing":"0001193125-26-027396","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526027396/ownership.xml","form_type":"4"}},{"id":929424,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":34272,"kind":"person","name":"Barone Francesca","position":1,"cik":"0001909680","reported_name":"Barone Francesca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-28T22:00:12.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":232000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":232000,"derivative":{"exercise_price":6.01,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":232000},"source":{"system":"sec-edgar","filing":"0001193125-26-027392","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909680/000119312526027392/ownership.xml","form_type":"4"}},{"id":928940,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-28T17:03:33.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":136500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":136500,"derivative":{"exercise_price":6.01,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":136500},"source":{"system":"sec-edgar","filing":"0001193125-26-027409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000119312526027409/ownership.xml","form_type":"4"}},{"id":929129,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68611,"kind":"person","name":"Schoch Charles","position":1,"cik":"0002007349","reported_name":"Schoch Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-28T17:02:42.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":232000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":232000,"derivative":{"exercise_price":6.01,"expiration_date":"2036-01-26","underlying":"Common Stock","underlying_shares":232000},"source":{"system":"sec-edgar","filing":"0001193125-26-027406","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007349/000119312526027406/ownership.xml","form_type":"4"}},{"id":1079078,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-30T16:30:16.000Z","date":"2025-07-28","kind":"exercise","planned":true,"acquired":false,"shares":937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":29377,"derivative":{"exercise_price":1.29,"expiration_date":"2033-04-28","underlying":"Common Stock","underlying_shares":937},"source":{"system":"sec-edgar","filing":"0000950170-25-100320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025100320/ownership.xml","form_type":"4"}},{"id":1079077,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-30T16:30:16.000Z","date":"2025-07-28","kind":"sale","planned":true,"acquired":false,"shares":937,"price":6.98,"value":6540.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."}],"balance_after":52493,"source":{"system":"sec-edgar","filing":"0000950170-25-100320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025100320/ownership.xml","form_type":"4"}},{"id":1079076,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-30T16:30:16.000Z","date":"2025-07-28","kind":"exercise","planned":true,"acquired":true,"shares":937,"price":1.29,"value":1208.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."}],"balance_after":53430,"source":{"system":"sec-edgar","filing":"0000950170-25-100320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025100320/ownership.xml","form_type":"4"}},{"id":1095128,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T16:30:04.000Z","date":"2025-06-30","kind":"exercise","planned":true,"acquired":false,"shares":781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":30314,"derivative":{"exercise_price":1.29,"expiration_date":"2033-04-28","underlying":"Common Stock","underlying_shares":781},"source":{"system":"sec-edgar","filing":"0000950170-25-093035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025093035/ownership.xml","form_type":"4"}},{"id":1095127,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-02T16:30:04.000Z","date":"2025-06-30","kind":"sale","planned":true,"acquired":false,"shares":781,"price":5.04,"value":3936.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."}],"balance_after":52493,"source":{"system":"sec-edgar","filing":"0000950170-25-093035","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025093035/ownership.xml","form_type":"4"}},{"id":1095126,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-02T16:30:04.000Z","date":"2025-06-30","kind":"exercise","planned":true,"acquired":true,"shares":781,"price":1.29,"value":1007.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."}],"balance_after":53274,"source":{"system":"sec-edgar","filing":"0000950170-25-093035","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025093035/ownership.xml","form_type":"4"}},{"id":1101170,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-06-26T12:30:14.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5353,"price":4.67,"value":24998.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."}],"balance_after":90865,"source":{"system":"sec-edgar","filing":"0000950170-25-090199","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000095017025090199/ownership.xml","form_type":"4"}},{"id":1100770,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-26T12:30:12.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":42826,"price":4.67,"value":199997.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."}],"balance_after":268566,"source":{"system":"sec-edgar","filing":"0000950170-25-090198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025090198/ownership.xml","form_type":"4"}},{"id":1101047,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-26T12:30:10.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":1070663,"price":4.67,"value":4999996.21,"ownership":{"direct":false,"nature":"By Paul B. Manning Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the \"Trust\"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein."}],"balance_after":2213069,"source":{"system":"sec-edgar","filing":"0000950170-25-090197","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000095017025090197/ownership.xml","form_type":"4"}},{"id":1101150,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35711,"kind":"person","name":"Martell Christopher","position":1,"cik":"0001873465","reported_name":"Martell Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-26T12:30:08.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":111349,"price":4.67,"value":519999.83,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Spouse."}],"balance_after":111349,"source":{"system":"sec-edgar","filing":"0000950170-25-090196","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873465/000095017025090196/ownership.xml","form_type":"4"}},{"id":1100771,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33751,"kind":"person","name":"Loggia Nicoletta","position":1,"cik":"0001979825","reported_name":"Loggia Nicoletta","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-26T12:30:07.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":2141,"price":4.67,"value":9998.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."}],"balance_after":2141,"source":{"system":"sec-edgar","filing":"0000950170-25-090195","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025090195/ownership.xml","form_type":"4"}},{"id":1100769,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35576,"kind":"person","name":"Nabel Gary J.","position":1,"cik":"0001867450","reported_name":"Nabel Gary J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-26T12:30:06.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5353,"price":4.67,"value":24998.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."}],"balance_after":5353,"source":{"system":"sec-edgar","filing":"0000950170-25-090192","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025090192/ownership.xml","form_type":"4"}},{"id":1101347,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":34272,"kind":"person","name":"Barone Francesca","position":1,"cik":"0001909680","reported_name":"Barone Francesca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-26T12:30:05.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":4282,"price":4.67,"value":19996.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."}],"balance_after":100809,"source":{"system":"sec-edgar","filing":"0000950170-25-090194","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909680/000095017025090194/ownership.xml","form_type":"4"}},{"id":1100948,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33888,"kind":"person","name":"PAPA JOSEPH C","position":1,"cik":"0001242215","reported_name":"PAPA JOSEPH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-26T12:30:04.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":64239,"price":4.67,"value":299996.13,"ownership":{"direct":false,"nature":"By Joseph C. Papa Revocable Living Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by Joseph C. Papa Revocable Living Trust, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any."}],"balance_after":64239,"source":{"system":"sec-edgar","filing":"0000950170-25-090191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242215/000095017025090191/ownership.xml","form_type":"4"}},{"id":1101181,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68611,"kind":"person","name":"Schoch Charles","position":1,"cik":"0002007349","reported_name":"Schoch Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-26T08:30:07.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5353,"price":4.67,"value":24998.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025."}],"balance_after":43391,"source":{"system":"sec-edgar","filing":"0000950170-25-090193","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007349/000095017025090193/ownership.xml","form_type":"4"}},{"id":1102845,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68611,"kind":"person","name":"Schoch Charles","position":1,"cik":"0002007349","reported_name":"Schoch Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T16:30:29.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. 25% of the shares underlying this option shall vest and become exercisable on June 20, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":4.75,"expiration_date":"2035-06-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-25-089473","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007349/000095017025089473/ownership.xml","form_type":"4"}},{"id":1106334,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35655,"kind":"person","name":"Benz Edward J. JR","position":1,"cik":"0001691160","reported_name":"Benz Edward J. JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T12:38:15.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":4.94,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-25-087708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691160/000095017025087708/ownership.xml","form_type":"4"}},{"id":1106377,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":22260,"kind":"person","name":"Gaeta Renee","position":1,"cik":"0001742428","reported_name":"Gaeta Renee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T12:37:10.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":4.94,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-25-087705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742428/000095017025087705/ownership.xml","form_type":"4"}},{"id":1105851,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33751,"kind":"person","name":"Loggia Nicoletta","position":1,"cik":"0001979825","reported_name":"Loggia Nicoletta","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T12:36:23.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":4.94,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-25-087703","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025087703/ownership.xml","form_type":"4"}},{"id":1106240,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T12:35:33.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":4.94,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-25-087702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494695/000095017025087702/ownership.xml","form_type":"4"}},{"id":1106485,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35711,"kind":"person","name":"Martell Christopher","position":1,"cik":"0001873465","reported_name":"Martell Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T12:34:55.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":4.94,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-25-087700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873465/000095017025087700/ownership.xml","form_type":"4"}},{"id":1105850,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35576,"kind":"person","name":"Nabel Gary J.","position":1,"cik":"0001867450","reported_name":"Nabel Gary J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T12:33:55.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":4.94,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-25-087699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025087699/ownership.xml","form_type":"4"}},{"id":1106407,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35681,"kind":"person","name":"Nguyen Diem","position":1,"cik":"0001814338","reported_name":"Nguyen Diem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T12:33:20.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":4.94,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-25-087698","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814338/000095017025087698/ownership.xml","form_type":"4"}},{"id":1106079,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":33888,"kind":"person","name":"PAPA JOSEPH C","position":1,"cik":"0001242215","reported_name":"PAPA JOSEPH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T12:32:30.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the \"Board\") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting."}],"balance_after":14240,"derivative":{"exercise_price":4.94,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14240},"source":{"system":"sec-edgar","filing":"0000950170-25-087697","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242215/000095017025087697/ownership.xml","form_type":"4"}},{"id":1120001,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":35728,"kind":"person","name":"Radhakrishnan Maha","position":1,"cik":"0002013423","reported_name":"Radhakrishnan Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:36:10.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":28480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":28480,"derivative":{"exercise_price":5.6,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":28480},"source":{"system":"sec-edgar","filing":"0000950170-25-083163","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013423/000095017025083163/ownership.xml","form_type":"4"}},{"id":1196297,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":34272,"kind":"person","name":"Barone Francesca","position":1,"cik":"0001909680","reported_name":"Barone Francesca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-20T20:36:03.000Z","date":"2025-03-18","kind":"exercise","planned":true,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vested and became exercisable on December 30, 2021, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":30822,"derivative":{"exercise_price":1.55,"expiration_date":"2030-12-30","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-042726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1909680/000095017025042726/ownership.xml","form_type":"4"}},{"id":1196296,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":34272,"kind":"person","name":"Barone Francesca","position":1,"cik":"0001909680","reported_name":"Barone Francesca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:36:03.000Z","date":"2025-03-18","kind":"sale","planned":true,"acquired":false,"shares":32146,"price":8.7623,"value":281672.8958,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.345 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."}],"balance_after":96527,"source":{"system":"sec-edgar","filing":"0000950170-25-042726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1909680/000095017025042726/ownership.xml","form_type":"4"}},{"id":1196295,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":34272,"kind":"person","name":"Barone Francesca","position":1,"cik":"0001909680","reported_name":"Barone Francesca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:36:03.000Z","date":"2025-03-18","kind":"exercise","planned":true,"acquired":true,"shares":18000,"price":1.55,"value":27900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."}],"balance_after":128673,"source":{"system":"sec-edgar","filing":"0000950170-25-042726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909680/000095017025042726/ownership.xml","form_type":"4"}},{"id":1195364,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:35:42.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":400,"price":9.0025,"value":3601.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/19/2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 herein."}],"balance_after":225740,"source":{"system":"sec-edgar","filing":"0000950170-25-042725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025042725/ownership.xml","form_type":"4"}},{"id":1195363,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:35:42.000Z","date":"2025-03-18","kind":"sale","planned":true,"acquired":false,"shares":25772,"price":8.7701,"value":226023.0172,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/19/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.33 to $9.01, inclusive."}],"balance_after":226140,"source":{"system":"sec-edgar","filing":"0000950170-25-042725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025042725/ownership.xml","form_type":"4"}},{"id":1195848,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-20T20:35:16.000Z","date":"2025-03-17","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.29,"expiration_date":"2033-04-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-042724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000095017025042724/ownership.xml","form_type":"4/A","original_submission_date":"2025-03-19"}},{"id":1195847,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:35:16.000Z","date":"2025-03-17","kind":"sale","planned":true,"acquired":false,"shares":31278,"price":8.8224,"value":275947.0272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.67 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."}],"balance_after":85512,"source":{"system":"sec-edgar","filing":"0000950170-25-042724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000095017025042724/ownership.xml","form_type":"4/A","original_submission_date":"2025-03-19"}},{"id":1195846,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:35:16.000Z","date":"2025-03-17","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":1.29,"value":25800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024."}],"balance_after":116790,"source":{"system":"sec-edgar","filing":"0000950170-25-042724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000095017025042724/ownership.xml","form_type":"4/A","original_submission_date":"2025-03-19"}},{"id":1195674,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-20T16:36:22.000Z","date":"2025-03-18","kind":"exercise","planned":true,"acquired":false,"shares":13905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":31095,"derivative":{"exercise_price":1.29,"expiration_date":"2033-04-28","underlying":"Common Stock","underlying_shares":13905},"source":{"system":"sec-edgar","filing":"0000950170-25-042728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025042728/ownership.xml","form_type":"4"}},{"id":1195673,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-20T16:36:22.000Z","date":"2025-03-18","kind":"exercise","planned":true,"acquired":false,"shares":4584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The first 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on September 12, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The remaining 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on the first anniversary of the date in which the Reporting Person converts to a full-time employee, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":195416,"derivative":{"exercise_price":3.75,"expiration_date":"2032-09-12","underlying":"Common Stock","underlying_shares":4584},"source":{"system":"sec-edgar","filing":"0000950170-25-042728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025042728/ownership.xml","form_type":"4"}},{"id":1195672,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-20T16:36:22.000Z","date":"2025-03-18","kind":"sale","planned":true,"acquired":false,"shares":45316,"price":8.7606,"value":396995.3496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.36 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."}],"balance_after":52493,"source":{"system":"sec-edgar","filing":"0000950170-25-042728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025042728/ownership.xml","form_type":"4"}},{"id":1195671,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-20T16:36:22.000Z","date":"2025-03-18","kind":"exercise","planned":true,"acquired":true,"shares":13905,"price":1.29,"value":17937.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."}],"balance_after":97809,"source":{"system":"sec-edgar","filing":"0000950170-25-042728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025042728/ownership.xml","form_type":"4"}},{"id":1195670,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-20T16:36:22.000Z","date":"2025-03-18","kind":"exercise","planned":true,"acquired":true,"shares":4584,"price":3.75,"value":17190.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024."}],"balance_after":83904,"source":{"system":"sec-edgar","filing":"0000950170-25-042728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025042728/ownership.xml","form_type":"4"}},{"id":1197332,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-19T20:12:18.000Z","date":"2025-03-17","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.29,"expiration_date":"2033-04-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-042002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000095017025042002/ownership.xml","form_type":"4"}},{"id":1197331,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-03-19T20:12:18.000Z","date":"2025-03-17","kind":"sale","planned":true,"acquired":false,"shares":31278,"price":8.8224,"value":275947.0272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.67 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."}],"balance_after":85512,"source":{"system":"sec-edgar","filing":"0000950170-25-042002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000095017025042002/ownership.xml","form_type":"4"}},{"id":1197373,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68611,"kind":"person","name":"Schoch Charles","position":1,"cik":"0002007349","reported_name":"Schoch Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-19T16:06:54.000Z","date":"2025-03-17","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":8.8338,"value":44169.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.74 to $8.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein."}],"balance_after":38038,"source":{"system":"sec-edgar","filing":"0000950170-25-041991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007349/000095017025041991/ownership.xml","form_type":"4"}},{"id":1245081,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2025-02-25T18:35:32.000Z","date":"2025-02-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10583,"price":12.02,"value":127207.66,"ownership":{"direct":true},"balance_after":162929,"source":{"system":"sec-edgar","filing":"0001873919-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391925000002/primary_doc.xml","form_type":"4"}},{"id":1245080,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2025-02-25T18:35:32.000Z","date":"2025-02-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10582,"price":12.02,"value":127195.64,"ownership":{"direct":false,"nature":"By LKA 2022 Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares of common stock held by spouse LKA 2022 Revocable trust"}],"balance_after":120861,"source":{"system":"sec-edgar","filing":"0001873919-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391925000002/primary_doc.xml","form_type":"4"}},{"id":1267671,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-14T21:30:06.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following February 12, 2025, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":65000,"derivative":{"exercise_price":8.55,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000950170-25-021292","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000095017025021292/ownership.xml","form_type":"4"}},{"id":1266540,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-14T21:30:05.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following February 12, 2025, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":525000,"derivative":{"exercise_price":8.55,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000950170-25-021283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025021283/ownership.xml","form_type":"4"}},{"id":1268642,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":34272,"kind":"person","name":"Barone Francesca","position":1,"cik":"0001909680","reported_name":"Barone Francesca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-14T21:30:03.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following February 12, 2025, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":115000,"derivative":{"exercise_price":8.55,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0000950170-25-021282","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909680/000095017025021282/ownership.xml","form_type":"4"}},{"id":1267698,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68611,"kind":"person","name":"Schoch Charles","position":1,"cik":"0002007349","reported_name":"Schoch Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-14T16:30:10.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":83000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following February 12, 2025, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":83000,"derivative":{"exercise_price":8.55,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":83000},"source":{"system":"sec-edgar","filing":"0000950170-25-021287","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007349/000095017025021287/ownership.xml","form_type":"4"}},{"id":1267277,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-14T16:30:07.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":107250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following February 12, 2025, subject to the Reporting Person's continued service on each vesting date."}],"balance_after":107250,"derivative":{"exercise_price":8.55,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":107250},"source":{"system":"sec-edgar","filing":"0000950170-25-021284","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025021284/ownership.xml","form_type":"4"}},{"id":1269195,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2025-02-13T11:25:21.000Z","date":"2025-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31335,"price":8.61,"value":269794.35,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Shares of common stock held jointly with spouse"}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001873919-25-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391925000001/primary_doc.xml","form_type":"4"}},{"id":1301028,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":34272,"kind":"person","name":"Barone Francesca","position":1,"cik":"0001909680","reported_name":"Barone Francesca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-17T21:30:08.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":13534,"price":7.225,"value":97783.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":110673,"source":{"system":"sec-edgar","filing":"0000950170-25-006726","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909680/000095017025006726/ownership.xml","form_type":"4"}},{"id":1300341,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-01-17T21:30:07.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":14322,"price":7.225,"value":103476.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":96790,"source":{"system":"sec-edgar","filing":"0000950170-25-006733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000095017025006733/ownership.xml","form_type":"4"}},{"id":1299552,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-17T21:30:05.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":21704,"price":7.225,"value":156811.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":251912,"source":{"system":"sec-edgar","filing":"0000950170-25-006724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025006724/ownership.xml","form_type":"4"}},{"id":1300379,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68611,"kind":"person","name":"Schoch Charles","position":1,"cik":"0002007349","reported_name":"Schoch Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-17T16:30:06.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":9511,"price":7.225,"value":68716.975,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":43038,"source":{"system":"sec-edgar","filing":"0000950170-25-006725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007349/000095017025006725/ownership.xml","form_type":"4"}},{"id":1300064,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-17T16:30:03.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":10428,"price":7.225,"value":75342.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":79320,"source":{"system":"sec-edgar","filing":"0000950170-25-006723","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025006723/ownership.xml","form_type":"4"}},{"id":1305988,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":34272,"kind":"person","name":"Barone Francesca","position":1,"cik":"0001909680","reported_name":"Barone Francesca","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:30:11.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":13673,"price":8.2182,"value":112367.4486,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":124207,"source":{"system":"sec-edgar","filing":"0000950170-25-004200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909680/000095017025004200/ownership.xml","form_type":"4"}},{"id":1304804,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68570,"kind":"person","name":"Tak Paul Peter","position":1,"cik":"0001873905","reported_name":"Tak Paul Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:30:08.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":21172,"price":8.2182,"value":173995.7304,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":273616,"source":{"system":"sec-edgar","filing":"0000950170-25-004198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025004198/ownership.xml","form_type":"4"}},{"id":1305438,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":21701,"kind":"person","name":"Tyagarajan Seshu","position":1,"cik":"0001923794","reported_name":"Tyagarajan Seshu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:30:06.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":14545,"price":8.2182,"value":119533.719,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":111112,"source":{"system":"sec-edgar","filing":"0000950170-25-004197","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923794/000095017025004197/ownership.xml","form_type":"4"}},{"id":1305473,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68611,"kind":"person","name":"Schoch Charles","position":1,"cik":"0002007349","reported_name":"Schoch Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-10T16:30:09.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":9971,"price":8.2182,"value":81943.6722,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":52549,"source":{"system":"sec-edgar","filing":"0000950170-25-004199","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007349/000095017025004199/ownership.xml","form_type":"4"}},{"id":1305185,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":68597,"kind":"person","name":"Nichols William Garrett","position":1,"cik":"0001618364","reported_name":"Nichols William Garrett","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-10T16:30:03.000Z","date":"2025-01-08","kind":"sale","planned":false,"acquired":false,"shares":10799,"price":8.2183,"value":88749.4217,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person."}],"balance_after":89748,"source":{"system":"sec-edgar","filing":"0000950170-25-004195","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618364/000095017025004195/ownership.xml","form_type":"4"}},{"id":1320249,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2024-12-31T00:37:56.000Z","date":"2024-12-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":8.85,"value":442500.0,"ownership":{"direct":false,"nature":"By LKA 2022 Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares of common stock held by spouse LKA 2022 Revocable trust"}],"balance_after":131443,"source":{"system":"sec-edgar","filing":"0001873919-24-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391924000011/primary_doc.xml","form_type":"4"}},{"id":1320248,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2024-12-31T00:37:56.000Z","date":"2024-12-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":8.85,"value":442500.0,"ownership":{"direct":true},"balance_after":173512,"source":{"system":"sec-edgar","filing":"0001873919-24-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391924000011/primary_doc.xml","form_type":"4"}},{"id":1320247,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2024-12-31T00:37:56.000Z","date":"2024-12-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":9.01,"value":450500.0,"ownership":{"direct":false,"nature":"By LKA 2022 Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares of common stock held by spouse LKA 2022 Revocable trust"}],"balance_after":181443,"source":{"system":"sec-edgar","filing":"0001873919-24-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391924000011/primary_doc.xml","form_type":"4"}},{"id":1320246,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2024-12-31T00:37:56.000Z","date":"2024-12-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":9.01,"value":450500.0,"ownership":{"direct":true},"balance_after":223512,"source":{"system":"sec-edgar","filing":"0001873919-24-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391924000011/primary_doc.xml","form_type":"4"}},{"id":1321378,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2024-12-26T18:59:16.000Z","date":"2024-12-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":8.82,"value":441000.0,"ownership":{"direct":false,"nature":"By LKA 2022 Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares of common stock held by spouse LKA 2022 Revocable trust"}],"balance_after":231443,"source":{"system":"sec-edgar","filing":"0001873919-24-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391924000010/primary_doc.xml","form_type":"4"}},{"id":1321377,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2024-12-26T18:59:16.000Z","date":"2024-12-24","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":50000,"price":8.82,"value":441000.0,"ownership":{"direct":true},"balance_after":273512,"source":{"system":"sec-edgar","filing":"0001873919-24-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391924000010/primary_doc.xml","form_type":"4"}},{"id":1321376,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2024-12-26T18:59:16.000Z","date":"2024-12-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":8.52,"value":426000.0,"ownership":{"direct":false,"nature":"By LKA 2022 Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares of common stock held by spouse LKA 2022 Revocable trust"}],"balance_after":281443,"source":{"system":"sec-edgar","filing":"0001873919-24-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391924000010/primary_doc.xml","form_type":"4"}},{"id":1321375,"issuer":{"id":4969,"kind":"organization","name":"Candel Therapeutics, Inc.","symbol":"CADL"},"owners":[{"id":82805,"kind":"person","name":"Aguilar-Cordova Estuardo","position":1,"cik":"0001873919","reported_name":"Aguilar-Cordova Estuardo","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82806,"kind":"person","name":"Aguilar Laura K.","position":2,"cik":"0001873915","reported_name":"Aguilar Laura K.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CADL","published_at":"2024-12-26T18:59:16.000Z","date":"2024-12-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":8.52,"value":426000.0,"ownership":{"direct":true},"balance_after":323512,"source":{"system":"sec-edgar","filing":"0001873919-24-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1841387/000187391924000010/primary_doc.xml","form_type":"4"}}],"next_cursor":"2024-12-26T18:59:16.000000Z,1321375"}